Nystatin: Package Insert and Label Information

NYSTATIN- nystatin suspension
PAI Holdings, LLC

Rx Only

DESCRIPTION

Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei.

Structural formula:

nystatin chemical structure
(click image for full-size original)

C 47 H 75 NO 17 MW 926.13

Nystatin Oral Suspension USP, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤ 1% v/v), artificial peppermint flavor, cherry flavor, citric acid, D&C Yellow No. 10, FD&C Red No. 40, glycerin, magnesium aluminum silicate, methylparaben, potassium phosphate dibasic, propylene glycol, propylparaben, purified water and sucrose.

CLINICAL PHARMACOLOGY

Pharmacokinetics

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

General

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

Teratogenic Effects

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

Pediatric Use

See DOSAGE AND ADMINISTRATION.

ADVERSE REACTIONS

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

To report SUSPECTED ADVERSE REACTIONS, contact Pharmaceutical Associates, Inc. at 1-800-845-8210 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (See CLINICAL PHARMACOLOGY, Pharmacokinetics).

DOSAGE AND ADMINISTRATION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.

HOW SUPPLIED

Nystatin Oral Suspension USP, 100,000 USP Nystatin Units per mL, is available in a cherry, peppermint flavored, light creamy yellow, ready-to-use suspension, supplied in the following oral dosage forms:

NDC 0121-0868-02: 2 fl oz (60mL) bottle with calibrated dropper

NDC 0121-0868-16: 16 fl oz (473mL) bottle

NDC 0121-0868-05: 5mL unit dose cup. Case contains 40 unit dose cups of 5 mL (NDC 0121-0868-40) packaged in 4 trays of 10 unit dose cups each, 50 unit dose cups of 5 mL (NDC 0121-0868-50) packaged in 5 trays of 10 unit dose cups each and 100 unit dose cups of 5 mL (NDC 0121-0868-00) packaged in 10 trays of 10 unit dose cups each.

Storage

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Avoid freezing.

R02/22

Pharmaceutical Associates, Inc.
Greenville, SC 29605
www.paipharma.com

PRINCIPAL DISPLAY PANEL — 60 mL Bottle Label

60 mL

NDC 0121-0868-02

Nystatin Oral Suspension, USP

100,000 units per mL

SHAKE WELL BEFORE USING

Packaged with Calibrated Dropper

DO NOT USE IF TAMPER EVIDENT
SEAL IS BROKEN OR MISSING.

Rx ONLY

Pharmaceutical Associates, Inc.

Greenville, SC 29605

Each mL of cherry, peppermint flavored oral suspension contains 100,000 units Nystatin, USP and alcohol (≤ 1% v/v).

USUAL DOSAGE: For Infants: 2 mL(200,000 units) four times daily (in infants and young children, use dropper to place one half of dose in each side of the mouth and avoid feeding feeding for 5 to 10 minutes). See insert.

WARNINGS: Keep this and all drugs out of reach of children. In case of accidenta loverdose, seek professional assistance or contact a Poison Control Center immediately.

Keep tightly closed. Protect from light.

Store at 20° to 25°C (68° to 77°F)

[See USP Controlled Room Temperature}.

AVOID FREEZING

X0868020120 R01/20

60 mL bottle label
(click image for full-size original)

PRINCIPAL DISPLAY PANEL — 5 mL Unit Dose Cup Label

Delivers 5 mL

NDC 0121-0868-05

NYSTATIN ORAL SUSPENSION, USP

500,000 units/5 mL

Alcohol ≤ 1% v/v SHAKE WELL

Package Not Child-Resistant

Rx ONLY

PHARMACEUTICAL ASSOCIATES, INC.,
GREENVILLE, SC 29605

SEE INSERT

A0868051021

5 mL unit dose cup label
(click image for full-size original)
NYSTATIN
nystatin suspension
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0121-0868
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
NYSTATIN (NYSTATIN) NYSTATIN 100000 [USP’U] in 1 mL
Inactive Ingredients
Ingredient Name Strength
ALCOHOL
ANHYDROUS CITRIC ACID
D&C YELLOW NO. 10
FD&C RED NO. 40
GLYCERIN
METHYLPARABEN
POTASSIUM PHOSPHATE, DIBASIC
PROPYLENE GLYCOL
PROPYLPARABEN
WATER
SUCROSE
MAGNESIUM ALUMINUM SILICATE
Product Characteristics
Color yellow (Light — Creamy) Score
Shape Size
Flavor CHERRY (w/Peppermint) Imprint Code
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0121-0868-02 60 mL in 1 BOTTLE, DROPPER None
2 NDC:0121-0868-16 473 mL in 1 BOTTLE None
3 NDC:0121-0868-40 4 TRAY in 1 CASE contains a TRAY
3 10 CUP, UNIT-DOSE in 1 TRAY This package is contained within the CASE (0121-0868-40) and contains a CUP, UNIT-DOSE (0121-0868-05)
3 NDC:0121-0868-05 5 mL in 1 CUP, UNIT-DOSE This package is contained within a TRAY and a CASE (0121-0868-40)
4 NDC:0121-0868-50 5 TRAY in 1 CASE contains a TRAY
4 10 CUP, UNIT-DOSE in 1 TRAY This package is contained within the CASE (0121-0868-50) and contains a CUP, UNIT-DOSE (0121-0868-05)
4 NDC:0121-0868-05 5 mL in 1 CUP, UNIT-DOSE This package is contained within a TRAY and a CASE (0121-0868-50)
5 NDC:0121-0868-00 10 TRAY in 1 CASE contains a TRAY
5 10 CUP, UNIT-DOSE in 1 TRAY This package is contained within the CASE (0121-0868-00) and contains a CUP, UNIT-DOSE (0121-0868-05)
5 NDC:0121-0868-05 5 mL in 1 CUP, UNIT-DOSE This package is contained within a TRAY and a CASE (0121-0868-00)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA203621 07/17/2020
Labeler — PAI Holdings, LLC (044940096)
Establishment
Name Address ID/FEI Operations
PAI Holdings, LLC dba Pharmaceutical Associates, Inc. 097630693 analysis (0121-0868), label (0121-0868), manufacture (0121-0868), pack (0121-0868)

Revised: 01/2023 PAI Holdings, LLC

DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.

As the leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. Our material is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2023. All Rights Reserved.